Citizens Jmp Increases Celcuity (NASDAQ:CELC) Price Target to $160.00

Key Points

• Citizens Jmp raised its price target on Celcuity from $150.00 to $160.00 and kept a "market outperform" rating, implying about a 9.29% upside from the prior close.
• Shares jumped 16.5% to $146.40 on heavy volume (1.16M vs. avg. 752k), giving Celcuity a market cap of about $7.08 billion and a 12‑month high near $148.00.
• Analyst coverage is largely positive—10 Buys, 1 Hold and 1 Sell—with a consensus "Moderate Buy" and an average target of $126.40, although several firms (Needham, Guggenheim, others) recently raised targets into the $157–$165 range.

Celcuity (NASDAQ:CELC - Get Free Report) had its price target raised by analysts at Citizens Jmp from $150.00 to $160.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a "market outperform" rating on the stock. Citizens Jmp's target price suggests a potential upside of 9.29% from the company's previous close.

CELC has been the subject of several other reports. Wolfe Research reissued an "outperform" rating and set a $110.00 target price on shares of Celcuity in a research report on Thursday, March 12th. Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a research report on Monday. Wall Street Zen downgraded shares of Celcuity from a "hold" rating to a "sell" rating in a research report on Saturday, April 25th. Needham & Company LLC upped their price objective on shares of Celcuity from $122.00 to $157.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Guggenheim upped their price objective on shares of Celcuity from $135.00 to $165.00 and gave the stock a "buy" rating in a research report on Monday. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $126.40.

Celcuity Stock Up 16.5%

Shares of NASDAQ:CELC traded up $20.75 during midday trading on Monday, hitting $146.40. 1,156,078 shares of the company's stock were exchanged, compared to its average volume of 752,601. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. The stock has a 50 day moving average price of $114.53 and a 200-day moving average price of $102.64. The company has a market cap of $7.08 billion, a PE ratio of -38.69 and a beta of 0.09. Celcuity has a 12 month low of $9.51 and a 12 month high of $148.00.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.09. On average, sell-side analysts anticipate that Celcuity will post -3.97 EPS for the current fiscal year.

Insiders Place Their Bets

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the business's stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total value of $330,810.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at $745,425.20. The trade was a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CELC. Creative Planning purchased a new position in Celcuity in the second quarter valued at about $177,000. Rhumbline Advisers lifted its stake in shares of Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company's stock valued at $570,000 after buying an additional 503 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Celcuity during the 2nd quarter valued at approximately $169,000. Quantinno Capital Management LP lifted its stake in shares of Celcuity by 20.7% during the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company's stock valued at $3,245,000 after buying an additional 41,756 shares in the last quarter. Finally, Paloma Partners Management Co lifted its stake in shares of Celcuity by 285.8% during the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company's stock valued at $1,097,000 after buying an additional 60,849 shares in the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.